STAAR Surgical Company STAA R2KR3KPHARMA
Company Overview
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Why Investors Should Care
Revenue has grown at a 10.1% CAGR over the past five years.
Operating margin of 18.7% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Jan 2026 Revenue of $239.44M (-23.7% YoY); net profit $-80.45M.
- Trailing 12 Months Year-on-year growth — revenue +119.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.14% |
| 1 Year: | 119.60% |
Stock Price Performance
| 1 Year: | -16.80% |
| 6 Months: | +27.14% |
| 3 Months: | -21.74% |
| 1 Month: | +1.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STAA STAAR Surgical Company R2KR3KPHARMA | 23.47 | -53.34 | $1.17B | 0.00% | -23.94% | -5.99% | 10.14% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 5.93M | 6.61M | 5.35M | - | 4.80M | 5.23M | 5.24M | - | 5.85M | 4.47M | 5.59M | - | 4.25M | 3.13M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 12.36M | 12.80M | 14.66M | 12.99M | 14.63M | 14.87M | 15.88M | 14.58M | 15.47M | 16.85M | 17.38M | 19.43M | 25.23M | 23.86M | 22.99M | 24.18M | 29.90M | 29.05M | 28.82M | 24.76M | 24.43M | 34.87M | 34.30M | 39.14M | 49.20M | 45.30M | 44.99M | 49.26M | 63.87M | 60.46M | 57.56M | 70.73M | 63.64M | 61.03M | 78.41M | 68.49M | 28.00M | 32.80M | 77.88M | 68.86M |
| Operating Income | -1.74M | -2.02M | - | -10.05M | -2.14M | -1.72M | - | -2.08M | -1.32M | 1.04M | - | 799.00K | 3.03M | 1.58M | - | 1.56M | 4.61M | 3.33M | - | -1.14M | -1.05M | 4.88M | - | 7.47M | 10.65M | 7.84M | - | 12.11M | 17.02M | 13.71M | 2.80M | 8.60M | 6.29M | -2.28M | 11.90M | 5.68M | -57.40M | -29.96M | 18.49M | 7.98M |
| Net Income | -1.60M | -1.75M | -842.00K | -8.04M | -2.14M | -1.78M | -167.00K | -2.20M | -971.00K | 1.17M | -138.00K | 583.00K | 1.83M | 1.46M | 1.10M | 1.37M | 3.91M | 2.39M | 6.38M | -134.00K | -1.17M | 3.89M | 3.33M | 4.99M | 8.57M | 6.02M | 4.92M | 9.60M | 13.04M | 10.26M | 2.71M | 6.06M | 4.82M | -3.34M | 7.38M | 9.98M | -54.21M | -16.81M | 8.88M | 5.21M |
| Diluted EPS | - | - | - | - | - | -0.04 | - | -0.05 | -0.02 | 0.03 | - | 0.01 | 0.04 | 0.03 | 0.02 | 0.03 | 0.08 | 0.05 | 0.14 | 0.00 | -0.03 | 0.08 | 0.07 | 0.10 | 0.17 | 0.12 | 0.10 | 0.19 | 0.26 | 0.21 | 0.05 | 0.12 | 0.10 | -0.07 | 0.15 | 0.20 | -1.10 | -0.34 | 0.18 | 0.10 |
| R&D Expense | 3.54M | 3.68M | - | 6.91M | 4.66M | 4.45M | - | 4.78M | 4.77M | 4.59M | - | 5.41M | 5.35M | 5.57M | - | 5.63M | 6.10M | 6.16M | - | 6.90M | 7.31M | 8.75M | - | 8.26M | 8.26M | 8.27M | - | 7.94M | 8.64M | 9.62M | 10.31M | 11.76M | 11.47M | 13.38M | 11.87M | 12.25M | 11.34M | 10.26M | 9.21M | 9.93M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.06M | 54.96M | 62.77M | 63.78M | 72.22M | 74.99M | 77.12M | 23.32M | 22.29M | 22.87M | 20.86M | 22.05M | 230.47M | 239.44M | 322.42M | 313.90M | 239.44M |
| Gross Profit | 31.32M | 35.08M | 42.37M | 44.29M | 50.31M | 48.82M | 52.72M | 58.37M | 64.28M | 91.51M | 111.95M | 118.36M | 178.64M | 223.38M | 252.65M | 239.58M | 182.42M |
| Operating Income | -4.88M | -2.60M | 2.78M | -1.22M | 700.00K | -8.03M | -5.34M | -12.65M | -3.63M | 6.59M | 11.85M | 6.77M | 33.34M | 43.80M | 28.10M | -12.61M | -91.71M |
| Net Income | -6.20M | 53.00K | 1.35M | -1.76M | 398.00K | -8.39M | -6.53M | -12.13M | -2.14M | 4.97M | 14.05M | 5.91M | 27.51M | 39.66M | 21.35M | -20.21M | -80.45M |
| Diluted EPS | -0.19 | 0.00 | 0.04 | -0.05 | 0.01 | -0.22 | -0.17 | -0.30 | -0.05 | 0.11 | 0.30 | 0.12 | 0.56 | 0.80 | 0.43 | -0.41 | -1.62 |
| R&D Expense | 5.89M | 5.72M | 5.87M | 6.44M | 6.71M | 12.36M | 14.76M | 20.67M | 20.04M | 22.03M | 25.30M | 31.92M | 33.86M | 35.98M | 40.48M | 45.32M | 40.05M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2009 | Dec 2009 | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 40.59M | 49.01M | 54.76M | 61.93M | 58.91M | 62.95M | 65.48M | 67.93M | 167.34M | 207.52M | 257.42M | 345.78M | 418.82M | 488.69M | 509.52M | 451.68M |
| Total Equity | 16.03M | 21.07M | 21.07M | 22.43M | 29.46M | 31.74M | 38.85M | 37.10M | 38.85M | 37.91M | 42.94M | 132.43M | 159.88M | 197.22M | 261.57M | 336.11M | 385.95M | 397.33M | 344.18M |
| Cash & Equivalents | 4.99M | 6.33M | 6.33M | 9.38M | 16.58M | 21.68M | 22.95M | 13.01M | 13.40M | 14.00M | 18.52M | 103.88M | 119.97M | 152.45M | 199.71M | 86.48M | 183.04M | 144.16M | 153.15M |
| Total Liabilities | - | - | - | 18.16M | 19.55M | 23.02M | 23.08M | 21.81M | 24.11M | 27.57M | 25.00M | 34.91M | 47.64M | 60.19M | 87.22M | 82.71M | 102.74M | 112.19M | 107.49M |
| Current Liabilities | - | - | - | 13.45M | 14.02M | 17.95M | 18.41M | 16.37M | 17.89M | 21.07M | 19.09M | 27.73M | 34.48M | 41.24M | 48.80M | 51.72M | 65.04M | 70.31M | 68.50M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.43M | -4.42M | 5.35M | 3.22M | - | - | -2.16M | 1.05M | 2.85M | 12.77M | 25.80M | 20.95M | 43.96M | 35.72M | 14.59M | 15.72M | -34.23M |
| Investing Cash Flow | -7.61M | 18.77M | -889.00K | -2.15M | - | - | -2.04M | -3.21M | -1.05M | -2.25M | -10.18M | -8.40M | -13.64M | -156.38M | 74.35M | -59.22M | 46.34M |
| Financing Cash Flow | 7.36M | -11.52M | 2.77M | 4.28M | - | - | 4.58M | 2.95M | 2.44M | 74.64M | 149.00K | 19.57M | 17.79M | 8.30M | 7.42M | 5.72M | -4.55M |
| Capital Expenditure | -553.00K | -320.00K | -962.00K | -2.27M | -3.45M | -4.05M | -2.04M | -3.21M | -1.05M | -2.25M | -10.10M | -8.40M | -13.64M | -18.11M | -18.19M | -23.39M | -5.82M |
| Free Cash Flow | 874.00K | -4.74M | 4.38M | 946.00K | - | - | -4.21M | -2.16M | 1.81M | 10.52M | 15.70M | 12.55M | 30.32M | 17.61M | -3.59M | -7.67M | -40.05M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.46M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Jan 2014 | Jan 2015 | Jan 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Jan 2020 | Jan 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 61.3% | 63.8% | 67.5% | 69.4% | 69.7% | 65.1% | 68.4% | 250.3% | 288.4% | 400.1% | 536.6% | 536.7% | 77.5% | 93.3% | 78.4% | 76.3% | 76.2% |
| Operating Margin % | -9.6% | -4.7% | 4.4% | -1.9% | 1.0% | -10.7% | -6.9% | -54.3% | -16.3% | 28.8% | 56.8% | 30.7% | 14.5% | 18.3% | 8.7% | -4.0% | -38.3% |
| Net Margin % | -12.1% | 0.1% | 2.1% | -2.8% | 0.6% | -11.2% | -8.5% | -52.0% | -9.6% | 21.7% | 67.3% | 26.8% | 11.9% | 16.6% | 6.6% | -6.4% | -33.6% |
| ROE % | -29.4% | 0.2% | 4.6% | -5.6% | 1.0% | -22.6% | -16.8% | -32.0% | -5.0% | 3.8% | 8.8% | 3.0% | 10.5% | 11.8% | 5.5% | -5.1% | -23.4% |
| ROCE % | - | -9.6% | 8.0% | -3.3% | 1.6% | -18.9% | -11.8% | -28.5% | -7.4% | 4.7% | 6.8% | 3.1% | 11.2% | 11.9% | 6.6% | -2.9% | -23.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Broadwood Capital, Inc. | 32.16% | 16.12M | $356.50M |
| 2 | Blackrock Inc. | 13.42% | 6.73M | $148.83M |
| 3 | Madison Avenue Partners, LP | 8.33% | 4.18M | $92.33M |
| 4 | Yunqi Capital Ltd | 6.50% | 3.26M | $72.02M |
| 5 | Point72 Asset Management, L.P. | 4.86% | 2.44M | $53.89M |
| 6 | Goldman Sachs Group Inc | 4.29% | 2.15M | $47.55M |
| 7 | Vanguard Portfolio Management LLC | 3.95% | 1.98M | $43.77M |
| 8 | State Street Corporation | 3.53% | 1.77M | $39.12M |
| 9 | Anatole Investment Management Ltd | 3.29% | 1.65M | $36.52M |
| 10 | Vanguard Capital Management LLC | 3.10% | 1.55M | $34.33M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STAA
Why Did STAA Stock Surge More Than 19% After-Hours Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNc010LWxMUVRkak9rX2dmY1pTQmY0OFdtLTFwdHpGM2czdmVpbXFUTnRQS0oxTzRnU1huQUVtVXVVUVU3UHJuVUhYLTlKNGVycGdGSnZHMDNsSVNSMlozNThoZ3JtNU95aDhBTUstT0oxR1JsUU1nZ21YaVNxLVhxaGJ6QTBCMDZPZFZCek…
STAAR Surgical (STAA) Stock May Be 13% Below Fair Value Following Q2 Earnings Preview - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOMXQzT29YcnkzblYwaHppZGo1MXNyZWVSYkd0MFpCeXFDaEx5bVNvczRmQUt2YkpKRlBUcTdNT2ladlk1LTJCQXpxREZEYnJyUHl5TEtDUVJzTEpVT25uQUh6YS1xOWwzVDJtaTJvcElKSVFaVFJieUdqMnptSkxRb0g4NGZyTjJNaDRnUD…
STAAR Surgical hires a CTO as it prepares new eye products - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPWlpoYVh0TWFNUk9ENTVTR2ZzbzNMSWwydUljSlRnMU5PVVhLb0wyekxKQUxHU3Z6RkdNN18zR0JRUGFYNWRRSURrUTAxTHBjUE1iZ1RWTkh0ZHAwTm1uYmhjRENmcWhOWnZVVE1FQWV3UlBNQlFDSVM2M3M1dXF5Ml8zVUpTYm1QVllCLT…
Does STAAR Surgical's (STAA) New CTO Appointment Signal a Turning Point in Its Innovation Strategy? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPeVF5TjdaNVhmTi0wUVB1NWhaYlJTVGVXeUoxRUNWbFVXOTRMbDVjbjhpcVBSM1NyZXVfLWl6ekdVc1NwNkctMVYwWnN4NWZBei1ZZ1JLdTAtWFNoNDlwSEJ1SUg3R19hYW1xNG51d3l5Uml5Z3lxRGR6SHRWUjE4bl84RWk1b3lBbXpmRE…
$STAA stock is down 8% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNT0VURDVuWHRTbWdzdkJ3SVV5TndtWHpjcEhuZTRacDM2c0FXa0JoNi1obk1YTzRVeTVGd0NtLU9yemF0Wk04X1V3cm1HSnFNckF3LXcyTWJLbW41TlQzZm5DWU1VRllRTWpHRmczSE5fZ2FuRGl1OFJSUWtHQlJVbmoyaV9WLXd2NXFuZ0…
(STAA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOUW5lWUt6R05VbDVSUWpneldHOEtIUG5JVlhfNF8yMlVNRGxqeWoxb29XTFZYWjczQXN4OEtPb0R4SVFtU1N5OVVRUDIzc0hudmQ5bkt6Y3BvN3dTT05LMElzUHE3T3Raa193d21HVVhYOHkwMWt5WVlmZjJ4RGJiZVY3d3VQemZrbzEycm…
STAA — Frequently Asked Questions
What is the current share price of STAAR Surgical Company (STAA)?
As of 2026-09-07 16:24 PDT, STAAR Surgical Company (STAA) trades at $23.47 on NasdaqGM. Its 52-week range is $16.10 to $33.34.
What is the market capitalisation of STAA?
STAAR Surgical Company (STAA) has a market capitalisation of $1.17B on NasdaqGM.
What is the P/E ratio of STAA?
STAA trades at a trailing price-to-earnings (P/E) ratio of -53.34. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.42.
What is the return on equity (ROE) of STAA?
STAA has a return on equity (ROE) of -5.99%. Its return on capital employed (ROCE) is -23.94%.
Is STAA a good stock to buy?
This page provides a data-driven analysis of STAAR Surgical Company (STAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.